These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 9484799

  • 1. Association of estramustine resistance in human prostatic carcinoma cells with modified patterns of tubulin expression.
    Sangrajrang S, Denoulet P, Laing NM, Tatoud R, Millot G, Calvo F, Tew KD, Fellous A.
    Biochem Pharmacol; 1998 Feb 01; 55(3):325-31. PubMed ID: 9484799
    [Abstract] [Full Text] [Related]

  • 2. Estramustine resistance correlates with tau over-expression in human prostatic carcinoma cells.
    Sangrajrang S, Denoulet P, Millot G, Tatoud R, Podgorniak MP, Tew KD, Calvo F, Fellous A.
    Int J Cancer; 1998 Aug 12; 77(4):626-31. PubMed ID: 9679768
    [Abstract] [Full Text] [Related]

  • 3. Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents.
    Ranganathan S, Dexter DW, Benetatos CA, Hudes GR.
    Biochim Biophys Acta; 1998 Jan 21; 1395(2):237-45. PubMed ID: 9473684
    [Abstract] [Full Text] [Related]

  • 4. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance.
    Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR.
    Cancer Res; 1996 Jun 01; 56(11):2584-9. PubMed ID: 8653701
    [Abstract] [Full Text] [Related]

  • 5. Interaction of estramustine with tubulin isotypes.
    Laing N, Dahllöf B, Hartley-Asp B, Ranganathan S, Tew KD.
    Biochemistry; 1997 Jan 28; 36(4):871-8. PubMed ID: 9020786
    [Abstract] [Full Text] [Related]

  • 6. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells.
    Ranganathan S, McCauley RA, Dexter DW, Hudes GR.
    Br J Cancer; 2001 Sep 01; 85(5):735-40. PubMed ID: 11531260
    [Abstract] [Full Text] [Related]

  • 7. Different microtubule network alterations induced by pachymatismin, a new marine glycoprotein, on two prostatic cell lines.
    Sangrajrang S, Zidane M, Berda P, Moré MT, Calvo F, Fellous A.
    Cancer Chemother Pharmacol; 2000 Sep 01; 45(2):120-6. PubMed ID: 10663626
    [Abstract] [Full Text] [Related]

  • 8. Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells.
    Speicher LA, Laing N, Barone LR, Robbins JD, Seamon KB, Tew KD.
    Mol Pharmacol; 1994 Nov 01; 46(5):866-72. PubMed ID: 7969073
    [Abstract] [Full Text] [Related]

  • 9. Estramustine depolymerizes microtubules by binding to tubulin.
    Dahllöf B, Billström A, Cabral F, Hartley-Asp B.
    Cancer Res; 1993 Oct 01; 53(19):4573-81. PubMed ID: 8402630
    [Abstract] [Full Text] [Related]

  • 10. Estramustine resistance.
    Sangrajrang S, Calvo F, Fellous A.
    Gen Pharmacol; 1999 Aug 01; 33(2):107-13. PubMed ID: 10461848
    [Abstract] [Full Text] [Related]

  • 11. Kinetic stabilization of microtubule dynamics by estramustine is associated with tubulin acetylation, spindle abnormalities, and mitotic arrest.
    Mohan R, Panda D.
    Cancer Res; 2008 Aug 01; 68(15):6181-9. PubMed ID: 18676841
    [Abstract] [Full Text] [Related]

  • 12. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action.
    Panda D, Miller HP, Islam K, Wilson L.
    Proc Natl Acad Sci U S A; 1997 Sep 30; 94(20):10560-4. PubMed ID: 9380674
    [Abstract] [Full Text] [Related]

  • 13. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine.
    Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD, Tew KD.
    J Natl Cancer Inst; 1994 May 04; 86(9):688-94. PubMed ID: 7908988
    [Abstract] [Full Text] [Related]

  • 14. Estramustine-binding protein (EMBP) content in four different cell lines and its correlation to estramustine induced metaphase arrest.
    Eklöv S, Mahdy E, Wester K, Björk P, Malmström PU, Busch C, Nilsson S.
    Anticancer Res; 1996 May 04; 16(4A):1819-22. PubMed ID: 8712706
    [Abstract] [Full Text] [Related]

  • 15. Selective antimitotic effects of estramustine correlate with its antimicrotubule properties on glioblastoma and astrocytes.
    Yoshida D, Cornell-Bell A, Piepmeier JM.
    Neurosurgery; 1994 May 04; 34(5):863-7; discussion 867-8. PubMed ID: 8052384
    [Abstract] [Full Text] [Related]

  • 16. Antimicrotubule effects of estramustine, an antiprostatic tumor drug.
    Stearns ME, Tew KD.
    Cancer Res; 1985 Aug 04; 45(8):3891-7. PubMed ID: 4016756
    [Abstract] [Full Text] [Related]

  • 17. Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro.
    Mareel MM, Storme GA, Dragonetti CH, De Bruyne GK, Hartley-Asp B, Segers JL, Rabaey ML.
    Cancer Res; 1988 Apr 01; 48(7):1842-9. PubMed ID: 3349462
    [Abstract] [Full Text] [Related]

  • 18. Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status.
    Serafin AM, Akudugu JM, Bohm L.
    Urol Res; 2002 Oct 01; 30(5):289-94. PubMed ID: 12389116
    [Abstract] [Full Text] [Related]

  • 19. Growth of prostatic cancer cells, DU 145, as multicellular spheroids and effects of estramustine.
    Essand M, Nilsson S, Carlsson J.
    Anticancer Res; 1993 Oct 01; 13(5A):1261-8. PubMed ID: 8239495
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of lipophilins as determinants of tumor cell response to estramustine.
    Tucker JM, Lipatova Z, Beljanski V, Townsend DM, Tew KD.
    J Pharmacol Exp Ther; 2005 Dec 01; 315(3):1158-62. PubMed ID: 16120813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.